Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ocular Therapeutix (OCUL) PT Lowered to $17 at BofA Securities, PT $17
March 3, 2025 11:48 AM ESTBofA Securities analyst Tazeen Ahmad lowered the price target on Ocular Therapeutix (NASDAQ: OCUL) to $17.00 (from $18.00) while maintaining a Buy rating.
The analyst comments "Ocular (OCUL) reported an amendment to the SPA for SOL-1 to include re-dosing at weeks 52 and 76. Mgmt underscored the 9-month... More
